Skip to content
What Causes What
MECHANISM+ INCREASES

GLP-1 receptor agonist → Wellbeing / quality of life

Higher GLP-1 receptor agonist increases Wellbeing / quality of life.

In the STEP 1 trial of weekly semaglutide 2.4 mg, more people crossed a meaningful threshold on the Impact of Weight on Quality of Life physical-function scale than on placebo: 51.8 percent versus 28.3 percent (Rubino 2024). The same direction showed up on SF-36 physical functioning.

Randomized trial · Moderate · N=1961

Supported by an experiment or a tightly identified design. Read the caveats.

Mechanism

The pen cuts weight. Stairs, work, and self-consciousness about size then get easier to score. That is a quality-of-life scale, not a depression diagnosis. Rubino, Bjorner, Rathor and colleagues (2024) pooled patient-reported scores from STEP 1 to 4. IWQOL-Lite-CT and SF-36 physical functioning were confirmatory secondary end points in STEP 1 and 2 (and SF-36 in STEP 4). More people on semaglutide 2.4 mg than on placebo crossed a meaningful within-person change on IWQOL physical function in STEP 1 (51.8 versus 28.3 percent) and STEP 2 (39.6 versus 29.5 percent). SF-36 physical functioning moved the same way. Other subscales rose numerically except Role Emotional in STEP 2. abstract_only. Wharton, Lingvay, Bogdanski and colleagues (2025) assigned 307 adults with overweight or obesity and no diabetes to daily oral semaglutide 25 mg or placebo for 64 weeks. IWQOL-Lite-CT Physical Function, a confirmatory secondary end point, improved on drug (P less than 0.001). abstract_only.

Caveats

Someone was assigned a pen, so the stamp is an RCT stamp. These scores track weight-related function. They are not a treatment for depression. A later meta-analysis of the same STEP programme found average SF-36 physical-functioning gains of about 1.7 points, below a 3.7-point within-person threshold. The share who crossed a threshold still favoured the pen. STEP 2 is type 2 diabetes; the other STEP files are obesity without diabetes. Gut symptoms were common. Did not hang the IWQOL validation paper, the oral-versus-injectable indirect comparison, or the Cochrane liraglutide review. This page is a journal entry. It is not medical advice and not a reason to start or stop a drug.

Effect

qualitative. STEP 1 IWQOL-Lite-CT Physical Function MWPC 51.8% vs 28.3%. SF-36 PF MWPC 39.8% vs 24.1%. Confirmatory secondary. Rubino 2024. OASIS 4 IWQOL PF P<0.001.

Nodes

Lifestyle & environmentGLP-1 receptor agonistPsychology & behaviorWellbeing / quality of life

Named confounders

Cite this page

What Causes What. “GLP-1 receptor agonist → Wellbeing / quality of life.” https://whatcauseswhat.org/edges/e-glp1-wellbeing (atlas updated 2026-09-02).

https://whatcauseswhat.org/edges/e-glp1-wellbeing

Papers